. Author manuscript; available in PMC: 2009 Jun 1.

Published in final edited form as: Cancer Prev Res (Phila). 2008 Mar 31;1(1):45–55. doi: 10.1158/1940-6207.CAPR-08-0034

Table 1.

AP-1 blockade reduces erbB2-induced mammary tumor incidence

Purpose	Genotype	No. mice	No. mice that developed mammary tumor	Tumor incidence (%)
Expt.	H^+/- T^+/- R^+/-, Dox(+)	16	9^*	56
Control	H^+/- T^+/- R^+/-, Dox(-)	18	18	100
Control	H^+/- T^-/- R^+/-, Dox(+)	22	22	100
Control	H^+/- T^-/- R^+/-, Dox(-)	25	23	92
Control	H^+/- T^+/- R^-/-, Dox(+)	32	31	97
Control	H^+/- T^+/- R^-/-, Dox(-)	31	28	90
Control	H^+/- T^-/- R^-/-, Dox(+)	15	14	93
Control	H^+/- T^-/- R^-/-, Dox(-)	19	18	95

NOTE: H^+/-, Her2 heterozygous; T^+/-, Tam67 heterozygous; R^+/-, rtTA heterozygous; Dox, doxycycline. Cutoff time was at 80 wk of age.

When 100% (18 of 18) of group 2 control mice developed mammary tumors, 56% (9 of 16) of group 1 experimental mice developed mammary tumors.